Oncology Impact Fund (Cayman) Management L.P. is 10% Owner at iTeos Therapeutics, Inc. (ITOS). They have made 12 open-market trades across 4 companies since 2019, most recently 2023-06-01.
CIK 0001721036
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $10.0M since 2019, against 11 sales. Too few scored purchases to measure a record yet.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 45% | 36% | 45% |
| Avg Move | +3.6% | +6.5% | +2.7% |
| Scored | 11 | 11 | 11 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ITOS | SELL | 2021-12-03 | 2021-12-07 | $33.72 | $5.6M | +29.8% | +26.0% | +5.6% |
| ITOS | SELL | 2021-11-26 | 2021-11-30 | $35.18 | $2.7M | -0.9% | +33.5% | +1.0% |
| ITOS | SELL | 2021-11-22 | 2021-11-24 | $36.57 | $8.9M | -8.9% | +28.7% | -2.3% |
| ITOS | SELL | 2021-10-15 | 2021-10-18 | $27.45 | $1.6M | -2.7% | +21.8% | +37.4% |
| ITOS | SELL | 2021-10-07 | 2021-10-12 | $27.23 | $4.6M | +1.6% | +10.3% | +55.1% |
| ITOS | SELL | 2021-09-16 | 2021-09-20 | $28.38 | $8.7M | +0.1% | +2.4% | +60.6% |
| ITOS | SELL | 2021-09-07 | 2021-09-08 | $29.03 | $4.1M | -5.2% | -4.8% | +16.8% |
| CGEM | SELL · 10b5-1 | 2021-08-27 | 2021-08-31 | $29.24 | $1.3M | +2.2% | -20.1% | -37.8% |
| CGEM | SELL | 2021-08-23 | 2021-08-25 | $29.35 | $4.6M | +9.6% | -12.9% | -28.2% |
| HARP | SELL | 2021-05-10 | 2021-05-12 | $21.04 | $2.9M | -6.9% | -24.4% | -53.8% |
| HARP | SELL | 2021-04-16 | 2021-04-20 | $19.04 | $1.4M | +17.6% | +5.5% | -33.7% |
| TCRR | BUY | 2019-02-19 | 2019-02-21 | $15.00 | $10.0M | +29.9% | +7.6% | -11.0% |
| HARP | SELL | 2019-02-12 | 2019-02-14 | $14.00 | $6K | +5.1% | -14.7% | -29.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.